The present invention relates to a device for treating heart failure. More specifically, the invention relates to a cardiac harness configured to be fit around at least a portion of a patient's heart.
Congestive heart failure (“CHF”) is characterized by the failure of the heart to pump blood at sufficient flow rates to meet the metabolic demand of tissues, especially the demand for oxygen. One characteristic of CHF is remodeling of at least portions of a patient's heart. Remodeling involves physical changes to the size, shape and thickness of the heart wall. For example, a damaged left ventricle may have some localized thinning and stretching of a portion of the myocardium. The thinned portion of the myocardium often is functionally impaired, and other portions of the myocardium attempt to compensate. As a result, the other portions of the myocardium may expand so that the stroke volume of the ventricle is maintained notwithstanding the impaired zone of the myocardium. Such expansion may cause the left ventricle to assume a somewhat spherical shape.
Cardiac remodeling often subjects the heart wall to increased wall tension or stress, which further impairs the heart's functional performance. Often, the heart wall will dilate further in order to compensate for the impairment caused by such increased stress. Thus, a vicious cycle can result, in which dilation leads to further dilation and greater functional impairment.
A harness is constructed of polyester filaments knit in a well known “Atlas knit” arrangement, such as that discussed in international patent Publication Number WO 01/95830 A2, which is incorporated herein by reference in its entirety. As such, the harness is flexible, and the fabric can stretch, even though the polyester filaments do not necessarily elastically deform upon stretching of the fabric. Such fabric stretch is mainly due to linearization of filaments and fiber crimp and geometric distortion of the knit pattern. Once these stretch factors are exhausted, the harness becomes inelastic, and will no longer expand elastically with an increase in size of a patient's heart.
With reference to
Historically, congestive heart failure has been managed with a variety of drugs. Devices have also been used to improve cardiac output. For example, left ventricular assist pumps help the heart to pump blood. Multi-chamber pacing has also been employed to optimally synchronize the beating of the heart chambers to improve cardiac output. Various skeletal muscles, such as the latissimus dorsi, have been used to assist ventricular pumping. Researchers and cardiac surgeons have also experimented with prosthetic “girdles” disposed around the heart. One such design is a prosthetic “sock” or “jacket” that is wrapped around the heart.
Although some of the above-discussed devices hold promise, there remains a need in the art for an improved device for treating CHF to prevent a remodeled heart from further remodeling and/or help reverse remodeling of a diseased heart.
In accordance with one embodiment of the present invention, a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The harness has an operating range of expansion having a minimum value of at least twenty percent. A change of twenty percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.116 N/cm (0.066 lbF/in).
In accordance with a further embodiment, the circumferential compliance of the harness over the operating range of expansion is greater than a longitudinal compliance of the harness.
In accordance with another embodiment of the present invention, a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The variation of load as a function of expansion through a selected range of expansion is generally in the form of y=ax+b where a and b are determined by linear regression. A first value of “a” corresponds to a first selected range of expansion of at least five percent, and a second value of “a” corresponds to a second selected range of expansion of at least five percent. The second range of expansion consists of values greater than the first range of expansion so as to be nonoverlapping with the first range, and the second value of “a” is no greater than said first value of “a.”
In accordance with another embodiment, the present invention provides a cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The variation of load as a function of expansion between twenty percent expansion and thirty percent expansion is generally in the form of y=ax+b where “a” and “b” are determined by linear regression. The linear regression of said variation of load as a function of expansion yields a coefficient of determination of at least about 0.8. The value of “a” is no greater than about 0.0058 N/cm per percent expansion (0.0033 lbF/in per percent expansion.
In another embodiment, the value of “a” is no greater than about 0.0035 N/cm per percent expansion (0.002 lbF/in per percent expansion).
In accordance with still a further embodiment of the present invention, a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The variation of load as a function of expansion through a selected range of expansion is generally in the form of y=cXZ+ax+b where c, a and b are determined by linear regression, and c is negative.
Further features and advantages of the present invention will become apparent to one of skill in the art in view of the Detailed Description of Preferred Embodiments which follows, when considered together with the attached drawings and claims.
This application relates to a method and apparatus for treating heart failure. As discussed in Applicants' co-pending application entitled “Expandable Cardiac Harness For Treating Congestive Heart Failure,” Ser. No. 09/634,043, which was filed on Aug. 8, 2000, the entirety of which is hereby expressly incorporated by reference herein, it is anticipated that remodeling of a diseased heart can be resisted or even reversed by alleviating the wall stresses in such a heart. The present application discusses certain embodiments and methods for supporting the cardiac wall. Additional embodiments and aspects are also discussed in Applicants' co-pending applications entitled “Cardiac Harness,” Ser. No. 10/656,733, filed Sep. 5, 2003, “Device for Treating Heart Failure,” Ser. No. 10/242,016, filed Sep. 10, 2002, and “Heart Failure Treatment Device and Method,” Ser. No. 10/287,723, filed Oct. 31, 2002, the entirety of each of which are hereby expressly incorporated by reference.
The term “cardiac harness” as used herein is a broad term that refers to a device fit onto a patient's heart to apply a compressive force on the heart during at least a portion of the cardiac cycle. Other devices that are intended to be fit onto a heart and are referred to in the art as “girdles,” “socks,” “jackets,” or the like are included within the meaning of “cardiac harness.”
The cardiac harness 32 illustrated in
In the embodiment illustrated in
With reference to
In the embodiment shown in
As the heart expands and contracts during diastole and systole, the contractile cells of the myocardium expand and contract. In a diseased heart, the myocardium may expand such that the cells are distressed and lose at least some contractility. Distressed cells are less able to deal with the stresses of expansion and contraction. As such, the effectiveness of heart pumping decreases.
As discussed above, and as discussed in more detail in the applications that are incorporated herein by reference, the undulating spring elements 34 exert a force in resistance to expansion of the heart 30. Collectively, the force exerted by the spring elements tends toward compressing the heart, thus alleviating wall stresses in the heart as the heart expands. Each strand of spring hinges is configured so that as the heart expands during diastole the spring hinges correspondingly expand, storing expansion forces as bending energy in the spring. As such, the stress load on the myocardium is partially relieved by the harness. This reduction in stress helps to decrease the workload of the heart, enabling the heart to more effectively pump blood and helping the myocardium cells to remain healthy and/or regain health.
It is to be understood that several embodiments of cardiac harnesses can be constructed and that such embodiments may have varying configurations, sizes, flexibilities, etc., yet still create a mildly compressive force on the heart so as to reduce wall stresses. As discussed in the above-referenced applications, such cardiac harnesses can be constructed from many suitable materials including various metals, fabrics, plastics and braided, woven and/or knit filaments. Suitable materials also include superelastic materials and materials that exhibit shape memory. For example, a preferred embodiment of a harness is constructed of Nitinol. Shape memory polymers can also be employed. Such shape memory polymers can include shape memory polyurethanes or other polymers such as those containing oligo(ecaprolactone) dimethacrylate and/or poly(e-caprolactone), which are available from mnemoScience. Further, some cardiac harness embodiments substantially encircle the heart, while others may employ spring members disposed over only a portion of the circumference of the heart or harness.
As just discussed, bending stresses are absorbed by the spring members 34 during diastole and are stored in the members as bending energy. During systole, when the heart pumps, the heart muscles contract and the heart becomes smaller. Simultaneously, bending energy stored within the spring members 34 is at least partially released, thereby providing an assist to the heart during systole. In a preferred embodiment, the compressive force exerted on the heart by the spring members of the harness comprises about ten percent to fifteen percent of the mechanical work done as the heart contracts during systole. Although the harness is not intended to replace ventricular pumping, the harness substantially assists the heart during systole.
With reference next to
In a mammalian heart, the heart muscle cells in the base region tend to expand and contract in a generally transverse direction during pumping of the heart. In the apex region, the heart muscles tend to expand and contract in a longitudinal direction. Between the apex and base regions of the heart, the heart muscles generally expand and contract in directions between the longitudinal and transverse directions. In the embodiment illustrated in
With next reference to
A plurality of connectors 82 interconnects adjacent rings 80. The connectors 82 have a length oriented longitudinally relative to the rings so as to create space between adjacent rings. Further, the connectors help to maintain proper alignment between adjacent rings, while allowing some relative movement therebetween. The illustrated harness is configured so that no spring members 34 overlap one another. As such, wear of the harness due to repeated flexing and relative movement of the spring members 34 is avoided. Preferably, the connectors 82 are formed of a semi-compliant material, such as silicone or other similar material. It is contemplated that the connectors 82 may comprise any medical grade polymer such as, but not limited to, polyethylene, polypropylene, polyurethane, nylon, PTFE and ePTFE.
In the embodiment illustrated in
It will be appreciated that the lengths of the elongate strands 36 are selected such that the resulting rings 80 are sized in conformity with the general anatomy of the patient's heart 30. More specifically, strands used in the apex portion of the harness are not as long as the strands used to form the base portion. As such, the harness generally tapers from the base 52 toward the apex 54 in order to generally follow the shape of the patient's heart. In another embodiment, the diameter of a ring 80b at the base of the harness is smaller than the diameter of the adjacent ring 80c. In this embodiment, the harness has a greatest diameter at a point between the base and apex ends, and tapers from that point to both the base and apex ends. Preferably, the point of greatest diameter is closer to the base end 52 than to the apex end 56. It is contemplated that the lengths of the strands, as well as the sizes of the spring members, may be selected according to the intended size of the cardiac harness 70 and/or the amount of compressive force the harness is intended to impart to the patient's heart.
With continued reference to
In the illustrated embodiment, the rings 80 are coated with dielectric material and the connectors 82 are formed of a nonconductive material. As such, each ring is electrically isolated from the other rings in the harness. Preferably, silicone tubing is advanced over a strand of spring members prior to forming the strand into a ring. In another embodiment, Nitinol wire is dip coated with an insulating material before or after being formed into rings.
Various materials and methods can be used to coat the harness with dielectric material. In the illustrated embodiment, the rings are coated with silicone rubber. Other acceptable materials include urethanes and ceramics, as well as various polymers and the like, including Parylene™, a dielectric polymer available from Union Carbide. The materials can be applied to a harness by various methods, such as dip coating and spraying, or any other suitable method.
As discussed above, adjacent rings 80 are joined to one another by connectors 82. In the embodiment illustrated in
In the embodiment illustrated in
When foreign objects or substances, such as a cardiac harness, are introduced onto or adjacent the heart, the body will tend to deposit tissue on or around the foreign object. For example, fibrin and collagen deposits will tend to accumulate on and around the heart after a cardiac harness is placed thereon. This scar tissue tends to be tough, though flexible, and will additionally resist expansion of the patient's heart.
In one preferred embodiment, a cardiac wall tension reduction device is constructed of a bioabsorbable material. As such, the device will dissolve after a predetermined period of time. When in place, however, the device will relieve cardiac wall tension. Once the device is installed on the heart, the patient's body will respond by depositing scar tissue on the device and around the heart. Preferably, the tissue at least partially encapsulates the heart. After the device dissolves, the scar tissue remains. Thus, although the implanted device no longer restricts or resists further cardiac expansion, the scar tissue resists such expansion. As such, a long term treatment for resisting further cardiac expansion is established without requiring a permanent implant.
A bioabsorbable cardiac wall tension reduction device can be formed of any bioabsorbable material. It is to be understood that many types of materials can be used, including bioabsorbable materials typically used in sutures, stents and the like. For purposes of this disclosure, bioabsorbable materials include materials that degrade or dissolve over time when placed within a human body, and include biodegradable materials. In preferred embodiments, FDA-approved materials such as polylactic acid (PLA) and polyglycolic acid (PGA) can be used. Other materials, including both synthetic and naturally-derived polymers can suitably be employed.
A bioabsorbable cardiac harness can be formed in accordance with any acceptable method and fashion. For example, a sheet of PGA or PLA can be molded to a shape that fits about the heart. Similarly, a sheet can be formed having holes or gaps that lend themselves to increased flexibility. Further, a device can be molded or cut to have a series of undulating spring members, as in the embodiments discussed above. Still further, a lattice structure may be used to provide elasticity and facilitate and/or direct scar growth in a desired manner and direction. Still further, bioabsorbable material can be provided as extruded fibers or filaments that can be woven, braided, knit, or the like so as to fit about the heart and constrain expansion thereof.
As discussed in the above-referenced applications, when a force is applied to relieve cardiac wall stresses, the working load on the heart is reduced. Reducing the working load allows the heart to at least partially rest, and appears to provide an opportunity for the heart to at least partially heal itself. For example, it is anticipated that a remodeled diseased heart can reverse-remodel so as to become more healthy if cardiac wall stresses are reduced. The effect of reducing wall stress can indeed lead to valuable and beneficial healing effects.
In another preferred embodiment, a cardiac wall tension reduction device is at least partially made of a bioabsorbable material that is combined with medically beneficial medicaments so that the beneficial medicaments are released as the bioabsorbable material dissolves. For example, bone marrow or stem cells can be provided so as to possibly stimulate myocardial regeneration. This type of treatment may help resolve an infarct, and promote healing of the heart. Of course, it is to be understood that any type of medicament anticipated to aid the heart can be combined with a bioabsorbable apparatus.
In another embodiment, a bioabsorbable cardiac harness can be combined with anti-fibrin drugs and/or other medications that resist the deposit or growth of body tissues around the installed harness. As such, the harness reduces heart wall stresses, giving the heart an opportunity to begin healing, but will not form extensive scar tissue. In this embodiment, the harness is adapted so that it will dissolve after a period of time sufficient to rest the heart so that it can continue its work without developing worsening symptoms of disease. Since little or no scar tissue is left behind after the harness dissolves, the rested heart will not be restricted by such tissue. Although, as discussed above, scar tissue can sometimes serve a beneficial purpose, some situations benefit from avoidance of scar tissue.
As discussed above, it is anticipated that the heart will reverse remodel when a harness reduces cardiac wall stress. As such, the heart may be smaller when a bioabsorbable harness dissolves than when the harness was installed. In accordance with one embodiment, a new, smaller harness is then to be placed on the heart, thus prompting further reverse remodeling. This process can be repeated as often as desired, until the heart has reached a desired size and health level. When the desired size is achieved, further harnesses may not be needed because the heart is healthy enough to maintain its size. Alternatively, a permanent harness may be installed to maintain the heart at the desired size. In a further embodiment, another bioabsorbable harness is installed, but without anti-tissue-growth drugs. As such, the heart becomes at least partially encapsulated in body tissues that will resist enlargement of the heart beyond the desired size. This helps the heart maintain the desired healthy size.
In still another preferred embodiment, foreign bodies are introduced about the heart so as to stimulate tissue growth that will at least partially encapsulate the heart. These foreign bodies need not be in the form of a cardiac harness, and need not impart any compressive force on the heart. However, these foreign bodies will stimulate fibrin/collagen or other tissue growth about the heart so as to at least partially encapsulate the heart in the tissue. The tissue will act as a sock or jacket to resist further expansion of the heart.
It is to be understood that such foreign matter can be bioabsorbable, but is not necessarily so. For example, the foreign matter can comprise a liquid or powder irritant specially adapted to stimulate fibrin or collagen growth. Such irritants may include shredded or powderized polyester or other plastics.
In another embodiment, foreign matter or a cardiac harness can be arranged around the heart so as to stimulate tissue growth at specified locations and in desired directions. For example, matter can be placed so as to stimulate tissue growth in a configuration that generally follows the directional expansion and contraction of heart muscle. For example, in
Introduction and placement of foreign material around the patient's heart can be performed via minimally-invasive methods. Minimally invasive methods can also be used to install a Nitinol, woven and/or bioabsorbable harness around the heart. Even less invasive methods can be used to place loose or detached foreign matter about the heart.
As a patient's heart enlarges during congestive heart failure, the annulus of certain valves, such as the mitral valve, tends to grow with the heart. Eventually, the valve annulus may increase in size to a point at which the leaflets are not large enough to completely close the valve. Another factor contributing to valve dysfunction is that as the heart enlarges, the geometry of the heart changes somewhat. Portions of the heart, such as the papillary muscles, are moved outwardly from the leaflets to which the papillary muscles are attached via the chordae tendinaea. These papillary muscles may be stretched so much that they prevent the valve leaflets from adequately engaging each other during valve closure. As such, the leaflets will not be able to fully close, and the valve will leak. Such valve leakage simply makes the patient's heart problems worse.
As discussed in the above-referenced application entitled “Heart Failure Treatment Device and Method,” a harness or collar can be configured to exert a compressive force on specific portions of a heart so as to help prevent or diminish valve dysfunction. For example, a collar-type device can be specially configured to fit around the AV groove region 92 of the heart 30.
With continued reference to
As discussed above, a cardiac harness applies a mild compressive force on a patient's heart. It is anticipated that embodiments of an AV groove collar 94 and papillary muscle band 96 will exert a more aggressive compressive force than a typical cardiac harness. In another embodiment, a permanent cardiac harness implant is coated with an irritant in the portions configured to engage the AV groove 92 and/or papillary muscle regions of the heart so as to provide a more dramatic stimulus for tissue growth in these portions. Thus, tissue growth in the AV groove and papillary muscle areas of the heart will be increased, providing further resistance to expansion in these areas.
In another embodiment, a bioabsorbable woven or knit AV groove collar 94 stimulates tissue growth in and around the AV groove so as to provide similar benefits without a permanent implant. A bioabsorbable papillary muscle band 96 is similarly provided. It is to be understood that the AV groove collar 94 and papillary muscle band 96 can be used independent of one another or in conjunction with one another and either independent of or in conjunction with a permanent or bioabsorbable cardiac harness. For example, a papillary muscle band can be placed on the heart before or after installation of a cardiac harness.
In still further embodiments, an AV groove collar 94 and papillary band 96 can be incorporated into a cardiac harness so as to apply specially-directed forces to the specific portions of the heart and to create specific regions of increased tissue growth.
In still another embodiment, an AV groove collar and/or papillary band is constructed of a bioabsorbable material and is configured to exert a force on a patient's heart within a first force range. A cardiac harness is provided and is configured to exert a force on the patient's heart within a second force range. The first range of force, which is to be exerted by the papillary band or AV groove collar, induces generally greater levels of force than the second range. As such, when the combination is installed on the patient's heart, a greater force is exerted at the AV groove or papillary band region of the heart than elsewhere. As time passes and the collar or band is absorbed, the applied force on the heart becomes more equalized. This arrangement enables treatment of acute valvular dysfunction by applying a greater degree of force in one area of the heart than is needed for the rest of the heart. Over time, as the rest of the heart remodels, no extra force is needed to treat valvular dysfunction and, in this embodiment, is no longer exerted.
In a variation of the above embodiment, the AV groove collar and/or papillary muscle band is formed from a bioabsorbable material and is configured to have a maximum dimension beyond which the collar/band will not deform. As such, a selected portion of the heart can be constrained to a specific size while the rest of the heart is not so constrained. This enables passive treatment of the heart as a whole while also addressing an acute issue. It is to be understood that, in other embodiments, a bioabsorbable member can temporarily apply a targeted, increased force in a desired portion of the patient's heart while an accompanying cardiac harness provides a more even, mild and permanent compressive force over a larger portion of the heart.
In the embodiments described above, the cardiac harness preferably applies a mild compressive force on the heart in order to achieve therapeutic benefits. An applied force or pressure within a therapeutic range is defined herein as a pressure of sufficient magnitude that, when applied to an organ such as the heart, results in a benefit to the organ. In one embodiment, the therapeutic range for a cardiac harness is between about 2-20 mmHg. More preferably, the therapeutic pressure is about 2-10 mmHg, and most preferably is between about 2-5 mmHg.
With reference next to
In the illustrated embodiment, the cardiac harness exerts a pressure in response to strain of the harness. For example, if the harness is strained about one hundred percent it will exert about 10 mm Hg on the heart. As the heart becomes smaller as a result of reverse remodeling, the percent strain of the harness will decrease, and the corresponding pressure exerted by the harness also will decrease. In the preferred embodiment, the harness is configured so that the applied pressure varies relatively little over a broad range of deformation. As such, the harness provides a therapeutic pressure even after the heart has reverse remodeled extensively.
For example, with continued reference to
In accordance with another embodiment, the harness represented by the test data of
With reference next to
With reference next to
The above-described test procedure allows measurement of the elasticity/deformation behavior of various embodiments of cardiac harnesses so that such embodiments can be compared. For consistency, testing preferably is performed at room temperature, preferably about 37° C. (98.6° F.). As discussed above, the load is applied along the length L of the test portion 110, which length L is taken in a direction along the circumference of the corresponding harness. Thus, the applied load represents and corresponds to a circumferential load of the harness. The percent tensile strain is also taken along the length L. As such, the percent tensile strain represents and corresponds to a percent of circumferential expansion of the harness above a zero load condition.
With reference next to
With reference also to
A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a one hundred percent strain condition. Representative test data points are set out in the plot of
With continued reference to
With reference next to
A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a one hundred percent strain condition. Representative test data points are set out in the plot of
With continued reference to
With reference next to
A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a one hundred percent strain condition. Representative test data points are set out in the plot of
With continued reference to
With reference next to
A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a one hundred percent strain condition. Representative test data points are set out in the plot of
With continued reference to
With continued reference to
Yet another embodiment of a cardiac harness comprises strands of spring elements formed of drawn Nitinol wire having a diameter of about 0.041 cm (0.016 in). The spring elements resemble the spring element shown in
A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a one hundred percent strain condition. A linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y=ax+b. The linear regression was performed using Microsoft™ Excel™ software, and yielded the function y=0.005x+0.0128 N/cm (y=0.003x+0.0073 lbF/in.). The linear regression function has a coefficient of determination R2 of about 0.9945.
In each of the embodiments discussed above, the compliance functions y=ax+b are determined based on test data between about zero percent strain and one hundred percent strain. It is anticipated that behavior of the harness test portions may change considerably if tested far beyond one hundred percent strain. However, it is to be understood that the tested range of expansion of about zero to one hundred percent represents a proposed operating range of expansion for each harness. In this operating range, the compliance behavior of the harness embodiments is known and predictable.
In accordance with one embodiment, the cardiac harness is sized and configured relative to a patient's heart so that the operating range of the harness is up to about seventy-five percent expansion. In another embodiment, the operating range of the harness is up to about fifty percent expansion. Although the tested embodiments have been tested only up to about one hundred percent expansion, it is to be understood that further testing may reveal acceptable behavior in ranges well above one hundred percent expansion. As such, an operating range of the harness should be taken to mean a range over which the compliance behavior of the harness is acceptable for its intended purpose of providing a mild compressive force to the patient's heart without defining a limit beyond which the heart cannot expand.
Further, it is to be understood that, by employing the compliance functions that are derived from the test data by linear regression, the compliance behavior of the associated harnesses can be predicted over any range of expansion or load. For example, with reference to the embodiment of
With reference to the embodiment of
Experimental studies indicate that a cardiac harness having compliance properties as in the embodiment of
As demonstrated by the several embodiments tested and discussed above, significant changes to the calculated compliance functions can be achieved by varying structural properties such as wire diameter, heat treatment, and dimensions of spring elements. It is anticipated that other cardiac harness embodiments can be constructed wherein a change of about twenty percent in circumferential expansion yields a change in circumferential load of about 0.116 N/cm (0.066 lbF/in), 0.035 N/cm (0.022 lbF/in), 0.032 N/cm (0.018 lbF/in), or any range between or below these values.
Testing harness embodiments as discussed above enables analysis of the behavior of the harness over its operating range. For example, the compliance function y=ax+b can be computed over the entire range of test data, as with the embodiments discussed above, or can be computed over only a selected range of test data. Pursuant to standard mathematical properties, the constant “a” represents the slope of the function.
With reference to the embodiment of
The analysis just discussed is helpful in analyzing cardiac harness compliance behavior to determine whether a cardiac harness exhibits desired behavior. For example, in a preferred embodiment, the second slope “a” is no greater than the first slope “a.” It is further helpful to analyze such behavior over only portions of the range of expansion that are expected to be used during operation of the harness. For example, in another preferred embodiment, the second slope “a” is no greater than the first slope “a” within an operational range of expansion of the harness of about zero to one hundred percent expansion. In further preferred embodiments, the first selected range of expansion is within a range between about twenty and thirty percent expansion, and the second selected range of expansion is within a range between about twenty-five and one hundred percent expansion. In yet another embodiment, the second selected range of expansion is within a range between about twenty-five and fifty percent expansion.
In the embodiments discussed above, the compliance function has been defined by linear regression of test data taken over a percent expansion between about zero and one hundred percent. It is to be understood that such an analysis may also be helpful if taken over a more limited range of percent expansion. For example, the operating range of the harness may, in some embodiments, be limited to such a range of expansion. In accordance with one embodiment, the variation of load as a function of expansion between about twenty to thirty percent expansion is represent by the compliance function y=ax+b in which “a” and “b” are determined by linear regression, and wherein the value of “a” is no greater than about 0.0058 N/cm per percent expansion 0.0058 N/cm per percent expansion (0.0033 lbF/in per percent expansion).
In the illustrated embodiments, the coefficients of determination have been very close to 1. More particularly, the coefficients of determination are greater than about 0.9 band, in some embodiments, greater than about 0.98. Preferably, a compliance function determined by linear regression has a coefficient of determination of at least about 0.8 in order to be helpful for analysis as discussed herein.
For each of the analyses discussed above, characteristics over certain exemplary ranges of expansion have been specifically discussed. It is to be understood that, at least for the test data and corresponding compliance functions disclosed herein, the properties of the corresponding harnesses can be analyzed over any range of circumferential expansion or load. Such varying ranges of analysis are contemplated by the test data and the compliance functions. Such analyses are advantageous for defining the behavior of the corresponding harness embodiment.
Although this invention has been disclosed in the context of several preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
This application is a division of U.S. Ser. No. 11/272,566 filed Nov. 9, 2005 now U.S. Pat. No. 7,097,613 which is a continuation-in-part application of U.S. Ser. No. 10/338,934, filed Jan. 7, 2003 now U.S. Pat. No. 7,174,896 which is based on and claims priority to U.S. Provisional Application No. 60/346,788, filed Jan. 7, 2002. The entirety of each of these applications is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1682119 | Field | Aug 1928 | A |
2278926 | Hartwell | Apr 1942 | A |
2826193 | Vineberg | Mar 1958 | A |
3464322 | Pequignot | Sep 1969 | A |
3513836 | Sausse | May 1970 | A |
3587567 | Schiff | Jun 1971 | A |
3613672 | Schiff | Oct 1971 | A |
3966401 | Hancock et al. | Jun 1976 | A |
3983863 | Janke et al. | Oct 1976 | A |
3988782 | Dardik et al. | Nov 1976 | A |
4011947 | Sawyer | Mar 1977 | A |
4048990 | Goetz | Sep 1977 | A |
4065816 | Sawyer | Jan 1978 | A |
4108161 | Samuels et al. | Aug 1978 | A |
4192293 | Asrican | Mar 1980 | A |
4211325 | Wright | Jul 1980 | A |
4261342 | Aranguren Duo | Apr 1981 | A |
4306318 | Mano et al. | Dec 1981 | A |
4372293 | Vijil-Rosales | Feb 1983 | A |
4403604 | Wilkinson et al. | Sep 1983 | A |
4428375 | Ellman | Jan 1984 | A |
4512471 | Kaster et al. | Apr 1985 | A |
4536893 | Parravicini | Aug 1985 | A |
4545783 | Vaughan | Oct 1985 | A |
4628937 | Hess et al. | Dec 1986 | A |
4630597 | Kantrowitz et al. | Dec 1986 | A |
4665906 | Jervis | May 1987 | A |
4690134 | Snyders | Sep 1987 | A |
4697703 | Will | Oct 1987 | A |
4750619 | Cohen et al. | Jun 1988 | A |
4821723 | Baker, Jr. et al. | Apr 1989 | A |
4827932 | Ideker et al. | May 1989 | A |
4834707 | Evans | May 1989 | A |
4838288 | Wright et al. | Jun 1989 | A |
4840626 | Linsky et al. | Jun 1989 | A |
4863016 | Fong et al. | Sep 1989 | A |
4878890 | Bilweis | Nov 1989 | A |
4936857 | Kulik | Jun 1990 | A |
4957477 | Lundback | Sep 1990 | A |
4960424 | Grooters | Oct 1990 | A |
4973300 | Wright | Nov 1990 | A |
4976730 | Kwan-Gett | Dec 1990 | A |
5031762 | Heacox | Jul 1991 | A |
5057117 | Atweh | Oct 1991 | A |
5067957 | Jervis | Nov 1991 | A |
5087243 | Avitall | Feb 1992 | A |
5098369 | Heilman et al. | Mar 1992 | A |
5106386 | Isner et al. | Apr 1992 | A |
5119804 | Anstadt | Jun 1992 | A |
5131905 | Grooters | Jul 1992 | A |
5150706 | Cox et al. | Sep 1992 | A |
5169381 | Snyders | Dec 1992 | A |
5186711 | Epstein | Feb 1993 | A |
5190546 | Jervis | Mar 1993 | A |
5192314 | Daskalakis | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5256132 | Snyders | Oct 1993 | A |
5279539 | Bohan et al. | Jan 1994 | A |
5290217 | Campos | Mar 1994 | A |
5333624 | Tovey | Aug 1994 | A |
5336254 | Brennen et al. | Aug 1994 | A |
5344442 | Deac | Sep 1994 | A |
5352184 | Goldberg et al. | Oct 1994 | A |
5356432 | Rutkow et al. | Oct 1994 | A |
5366460 | Eberbach | Nov 1994 | A |
5383840 | Heilman et al. | Jan 1995 | A |
5385156 | Oliva | Jan 1995 | A |
5385229 | Bittmann et al. | Jan 1995 | A |
5385528 | Wilk | Jan 1995 | A |
5405360 | Tovey | Apr 1995 | A |
5429584 | Chiu | Jul 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5456711 | Hudson | Oct 1995 | A |
5460962 | Kemp | Oct 1995 | A |
5500015 | Deac | Mar 1996 | A |
5507779 | Altman | Apr 1996 | A |
5509428 | Dunlop | Apr 1996 | A |
5524633 | Heaven et al. | Jun 1996 | A |
5533958 | Wilk | Jul 1996 | A |
5534024 | Rogers et al. | Jul 1996 | A |
5545210 | Hess et al. | Aug 1996 | A |
5558617 | Heilman et al. | Sep 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5582616 | Bolduc et al. | Dec 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5593424 | Northrup III | Jan 1997 | A |
5593441 | Lichtenstein et al. | Jan 1997 | A |
5597378 | Jervis | Jan 1997 | A |
5603337 | Jarvik | Feb 1997 | A |
5607477 | Schindler et al. | Mar 1997 | A |
5647372 | Tovey et al. | Jul 1997 | A |
5647380 | Campbell et al. | Jul 1997 | A |
5695525 | Mulhauser et al. | Dec 1997 | A |
5702343 | Alferness | Dec 1997 | A |
5713954 | Rosenberg et al. | Feb 1998 | A |
5727569 | Benetti et al. | Mar 1998 | A |
5749839 | Kovacs | May 1998 | A |
5782746 | Wright | Jul 1998 | A |
5800334 | Wilk | Sep 1998 | A |
5800528 | Lederman et al. | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5824028 | Knisley | Oct 1998 | A |
5836311 | Borst et al. | Nov 1998 | A |
5848962 | Feindt et al. | Dec 1998 | A |
5849005 | Garrison et al. | Dec 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5876432 | Lau et al. | Mar 1999 | A |
5904690 | Middleman et al. | May 1999 | A |
5910124 | Rubin | Jun 1999 | A |
5927284 | Borst et al. | Jul 1999 | A |
5948019 | Shu et al. | Sep 1999 | A |
5957977 | Melvin | Sep 1999 | A |
5961440 | Schweich, Jr. et al. | Oct 1999 | A |
5976069 | Navia et al. | Nov 1999 | A |
5979456 | Magovern | Nov 1999 | A |
5984857 | Buck et al. | Nov 1999 | A |
5990378 | Ellis | Nov 1999 | A |
6007486 | Hunt et al. | Dec 1999 | A |
6015378 | Borst et al. | Jan 2000 | A |
6024096 | Buckberg | Feb 2000 | A |
6045497 | Schweich, Jr. et al. | Apr 2000 | A |
6050936 | Schweich, Jr. et al. | Apr 2000 | A |
6059715 | Schweich, Jr. et al. | May 2000 | A |
6071303 | Laufer | Jun 2000 | A |
6076013 | Brennan et al. | Jun 2000 | A |
6077214 | Mortier et al. | Jun 2000 | A |
6077218 | Alferness | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6085754 | Alferness et al. | Jul 2000 | A |
6095968 | Snyders | Aug 2000 | A |
6110100 | Talpade | Aug 2000 | A |
6117159 | Huebsch et al. | Sep 2000 | A |
6117979 | Hendriks et al. | Sep 2000 | A |
6123662 | Alferness et al. | Sep 2000 | A |
6125852 | Stevens et al. | Oct 2000 | A |
6126590 | Alferness | Oct 2000 | A |
6155968 | Wilk | Dec 2000 | A |
6155972 | Nauertz et al. | Dec 2000 | A |
6162168 | Schweich, Jr. et al. | Dec 2000 | A |
6165119 | Schweich, Jr. et al. | Dec 2000 | A |
6165120 | Schweich, Jr. et al. | Dec 2000 | A |
6165121 | Alferness | Dec 2000 | A |
6165122 | Alferness | Dec 2000 | A |
6166184 | Hendriks et al. | Dec 2000 | A |
6169922 | Alferness et al. | Jan 2001 | B1 |
6174279 | Girard | Jan 2001 | B1 |
6179791 | Krueger | Jan 2001 | B1 |
6183411 | Mortier et al. | Feb 2001 | B1 |
6190408 | Melvin | Feb 2001 | B1 |
6192280 | Sommer et al. | Feb 2001 | B1 |
6193648 | Krueger | Feb 2001 | B1 |
6206820 | Kazi et al. | Mar 2001 | B1 |
6214047 | Melvin | Apr 2001 | B1 |
6217894 | Sawhney et al. | Apr 2001 | B1 |
6221103 | Melvin | Apr 2001 | B1 |
6224540 | Lederman et al. | May 2001 | B1 |
6230714 | Alferness et al. | May 2001 | B1 |
6260552 | Mortier et al. | Jul 2001 | B1 |
6261222 | Schweich, Jr. et al. | Jul 2001 | B1 |
6264602 | Mortier et al. | Jul 2001 | B1 |
6282445 | Reinhardt et al. | Aug 2001 | B1 |
6287250 | Peng et al. | Sep 2001 | B1 |
6293906 | Vanden Hoek et al. | Sep 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6312725 | Wallace et al. | Nov 2001 | B1 |
6352710 | Sawhney et al. | Mar 2002 | B2 |
6360749 | Jayaraman | Mar 2002 | B1 |
6375608 | Alferness | Apr 2002 | B1 |
6390976 | Spence et al. | May 2002 | B1 |
6402679 | Mortier et al. | Jun 2002 | B1 |
6402680 | Mortier et al. | Jun 2002 | B2 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6409760 | Melvin | Jun 2002 | B1 |
6416459 | Haindl | Jul 2002 | B1 |
6425856 | Shapland et al. | Jul 2002 | B1 |
6432039 | Wardle | Aug 2002 | B1 |
6451025 | Jervis | Sep 2002 | B1 |
6482146 | Alferness et al. | Nov 2002 | B1 |
6517570 | Lau et al. | Feb 2003 | B1 |
6537203 | Alferness et al. | Mar 2003 | B1 |
6544168 | Alferness | Apr 2003 | B2 |
6547716 | Milbocker | Apr 2003 | B1 |
6547821 | Taylor et al. | Apr 2003 | B1 |
6564094 | Alferness et al. | May 2003 | B2 |
6567699 | Alferness et al. | May 2003 | B2 |
6569082 | Chin | May 2003 | B1 |
6572533 | Shapland et al. | Jun 2003 | B1 |
6575921 | Vanden Hoek et al. | Jun 2003 | B2 |
6579226 | Vanden Hoek et al. | Jun 2003 | B2 |
6582355 | Alferness et al. | Jun 2003 | B2 |
6587734 | Okuzumi | Jul 2003 | B2 |
6595912 | Lau et al. | Jul 2003 | B2 |
6602184 | Lau et al. | Aug 2003 | B2 |
6612978 | Lau et al. | Sep 2003 | B2 |
6612979 | Lau et al. | Sep 2003 | B2 |
6620095 | Taheri | Sep 2003 | B2 |
6633780 | Berger | Oct 2003 | B1 |
6645139 | Haindl | Nov 2003 | B2 |
6663558 | Lau et al. | Dec 2003 | B2 |
6673009 | Vanden Hoek et al. | Jan 2004 | B1 |
6682474 | Lau et al. | Jan 2004 | B2 |
6682475 | Cox et al. | Jan 2004 | B2 |
6682476 | Alferness et al. | Jan 2004 | B2 |
6685620 | Gifford, III et al. | Feb 2004 | B2 |
6685627 | Jayaraman | Feb 2004 | B2 |
6689048 | Vanden Hoek et al. | Feb 2004 | B2 |
6695769 | French et al. | Feb 2004 | B2 |
6699259 | Fogarty et al. | Mar 2004 | B2 |
6701929 | Hussein | Mar 2004 | B2 |
6702732 | Lau et al. | Mar 2004 | B1 |
6723041 | Lau et al. | Apr 2004 | B2 |
6730016 | Walsh et al. | May 2004 | B1 |
6755779 | Vanden Hoek et al. | Jun 2004 | B2 |
6759431 | Hunter et al. | Jul 2004 | B2 |
6818018 | Sawhney | Nov 2004 | B1 |
6833408 | Sehl et al. | Dec 2004 | B2 |
6876887 | Okuzumi | Apr 2005 | B2 |
6881185 | Vanden Hock et al. | Apr 2005 | B2 |
6887192 | Whayne et al. | May 2005 | B1 |
6893392 | Alferness | May 2005 | B2 |
6896652 | Alferness et al. | May 2005 | B2 |
6902522 | Walsh et al. | Jun 2005 | B1 |
6902524 | Alferness et al. | Jun 2005 | B2 |
6908426 | Shapland et al. | Jun 2005 | B2 |
7022063 | Lau et al. | Apr 2006 | B2 |
7077802 | Lau et al. | Jul 2006 | B2 |
7081086 | Lau et al. | Jul 2006 | B2 |
7097613 | Lau et al. | Aug 2006 | B2 |
7291105 | Lau et al. | Nov 2007 | B2 |
20010029314 | Alferness et al. | Oct 2001 | A1 |
20010047122 | Vanden Hoek et al. | Nov 2001 | A1 |
20020007216 | Melvin | Jan 2002 | A1 |
20020022880 | Melvin | Feb 2002 | A1 |
20020028981 | Lau et al. | Mar 2002 | A1 |
20020052538 | Lau et al. | May 2002 | A1 |
20020068849 | Schweich, Jr. et al. | Jun 2002 | A1 |
20020077524 | Schweich, Jr. et al. | Jun 2002 | A1 |
20020077637 | Vargas et al. | Jun 2002 | A1 |
20020082647 | Alferness et al. | Jun 2002 | A1 |
20020091296 | Alferness | Jul 2002 | A1 |
20020103511 | Alferness et al. | Aug 2002 | A1 |
20030004547 | Owen et al. | Jan 2003 | A1 |
20030023296 | Osypka | Jan 2003 | A1 |
20030060674 | Gifford, III et al. | Mar 2003 | A1 |
20030060677 | French et al. | Mar 2003 | A1 |
20030060895 | French et al. | Mar 2003 | A1 |
20030065248 | Lau et al. | Apr 2003 | A1 |
20030199733 | Shapland et al. | Oct 2003 | A1 |
20030199955 | Struble et al. | Oct 2003 | A1 |
20030229265 | Girard et al. | Dec 2003 | A1 |
20040102804 | Chin | May 2004 | A1 |
20040106848 | Lau et al. | Jun 2004 | A1 |
20040122069 | Glombik et al. | Jun 2004 | A1 |
20040171907 | Alferness et al. | Sep 2004 | A1 |
20040171908 | Alferness et al. | Sep 2004 | A1 |
20040210104 | Lau et al. | Oct 2004 | A1 |
20040230091 | Lau et al. | Nov 2004 | A1 |
20050033322 | Lau et al. | Feb 2005 | A1 |
20050049611 | Lau et al. | Mar 2005 | A1 |
20050055032 | Lau et al. | Mar 2005 | A1 |
20050059854 | Hoek et al. | Mar 2005 | A1 |
20050059855 | Lau et al. | Mar 2005 | A1 |
20050085688 | Girard et al. | Apr 2005 | A1 |
20050090707 | Lau et al. | Apr 2005 | A1 |
20050102010 | Lau et al. | May 2005 | A1 |
20050102016 | Lau et al. | May 2005 | A1 |
20050107661 | Lau et al. | May 2005 | A1 |
20050119717 | Lau et al. | Jun 2005 | A1 |
20050137673 | Lau et al. | Jun 2005 | A1 |
20050169958 | Hunter et al. | Aug 2005 | A1 |
20050169959 | Hunter et al. | Aug 2005 | A1 |
20050182290 | Lau et al. | Aug 2005 | A1 |
20050256368 | Klenk et al. | Nov 2005 | A1 |
20050283042 | Meyer et al. | Dec 2005 | A1 |
Number | Date | Country |
---|---|---|
3831 540 | Apr 1989 | DE |
295 17 393 | Mar 1996 | DE |
0 370 931 | May 1990 | EP |
0 280 564 | Jun 1993 | EP |
0 583 012 | Jul 1996 | EP |
0 791 330 | Aug 1997 | EP |
0 919 193 | Jun 1999 | EP |
2 527 435 | Dec 1983 | FR |
2 645 739 | Oct 1990 | FR |
2 115 287 | Sep 1983 | GB |
2 209 678 | May 1989 | GB |
1-271829 | Oct 1989 | JP |
331620628-13 | Apr 1983 | SU |
1734767 | May 1992 | SU |
WO 9119465 | Dec 1991 | WO |
WO 9506447 | Mar 1995 | WO |
WO 9604852 | Feb 1996 | WO |
WO 9640356 | Dec 1996 | WO |
WO 9720505 | Jun 1997 | WO |
WO 9724101 | Jul 1997 | WO |
WO 9803213 | Jan 1998 | WO |
WO 9814136 | Apr 1998 | WO |
WO 9826738 | Jun 1998 | WO |
WO 9829041 | Jul 1998 | WO |
WO 9858598 | Dec 1998 | WO |
WO 0002500 | Jan 1999 | WO |
WO 9911201 | Mar 1999 | WO |
WO 9930647 | Jun 1999 | WO |
WO 9944534 | Sep 1999 | WO |
WO 9944680 | Sep 1999 | WO |
WO 9953977 | Oct 1999 | WO |
WO 9956655 | Nov 1999 | WO |
WO 0006026 | Feb 2000 | WO |
WO 0006027 | Feb 2000 | WO |
WO 0006028 | Feb 2000 | WO |
WO 0013722 | Mar 2000 | WO |
WO 0016700 | Mar 2000 | WO |
WO 0018320 | Apr 2000 | WO |
WO 0028912 | May 2000 | WO |
WO 0028918 | May 2000 | WO |
WO0036995 | Jun 2000 | WO |
WO 0042919 | Jul 2000 | WO |
WO 0045735 | Aug 2000 | WO |
WO 0048795 | Aug 2000 | WO |
WO 0062727 | Oct 2000 | WO |
WO 0074769 | Dec 2000 | WO |
WO 0117437 | Mar 2001 | WO |
WO 0121098 | Mar 2001 | WO |
WO 0150981 | Jul 2001 | WO |
WO 0167985 | Sep 2001 | WO |
WO 0185061 | Nov 2001 | WO |
WO 0191667 | Dec 2001 | WO |
WO 0195830 | Dec 2001 | WO |
WO 0195831 | Dec 2001 | WO |
WO 0195832 | Dec 2001 | WO |
WO 0213726 | Feb 2002 | WO |
WO 0219917 | Mar 2002 | WO |
WO 03026483 | Apr 2003 | WO |
WO 03026484 | Apr 2003 | WO |
WO 03026485 | Apr 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20070021652 A1 | Jan 2007 | US |
Number | Date | Country | |
---|---|---|---|
60346788 | Jan 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11272566 | Nov 2005 | US |
Child | 11511091 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10338934 | Jan 2003 | US |
Child | 11272566 | US |